Blood Pressure Monitoring in Hemodialysis Patients With or Without Renin Angiotensin Aldosterone System (RAAS) Inhibitors: A Comparative Study

Abstract

Cardiovascular complications are the prime cause of morbidity and mortality in patients with end-stage renal disease leading to haemodialysis. Most of these patients have hypertension, and adequate control of blood pressure is challenging due to the multifactorial aetiology. The present study aims to evaluate the efficacy of RAAS and Non-RAAS inhibitors that can provide better control of blood pressure and improve the quality of life in haemodialysis patients. A Prospective observational study was carried out on the patients who attended the Haemodialysis unit of KIM's hospital and the study was conducted for 6 months; data on antihypertensive drugs and blood pressure control (pre-dialysis and post-dialysis) were recorded and analyzed. The mean and deviated pre and post systolic blood pressure of patients receiving RAAS inhibitors were found to be 150.6 ± 13.4 & 162 ± 20.9 and the diastolic pre and post blood pressure was found to be 83.3 ± 13.7 & 87.2 ± 11. The mean and deviated pre and post-systolic blood pressure of patients receiving Non-RAAS inhibitors were found to be 152.04 ± 15.2 & 161.6 ± 24.2 and the diastolic pre and post-blood pressure were found to be 83.6 ± 13.7 & 86.1 ± 7.8 as well. The study concluded the efficacy of RAAS and Non-RAAS inhibitors in the management of hypertension in haemodialysis patients have shown similar results.